Medeon Biodesign, Inc. (TPEX:6499)

Medeon Biodesign Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	693.43	513.37	1,238	483.9	735.32	1,128
Short-Term Investments	66.66	652.18	862.1	1,025	1,608	1,058
Trading Asset Securities	37.97	41.66	41.93	37.87	6.48	-
Cash & Short-Term Investments	798.05	1,207	2,142	1,547	2,350	2,186
Cash Growth	-51.38%	-43.64%	38.44%	-34.16%	7.49%	21.44%
Accounts Receivable	62.04	37.84	41.77	32.35	10.12	164.81
Other Receivables	5.07	7.71	8.37	26.65	5.12	5.5
Receivables	67.11	45.55	50.15	59.01	15.25	170.31
Inventory	26.18	34.1	10.77	10.06	-	45.48
Prepaid Expenses	26.5	30.34	24.89	21.42	24.68	17.75
Total Current Assets	917.84	1,317	2,228	1,638	2,390	2,420
Property, Plant & Equipment	302.2	355.47	321.82	340.24	44.52	666.03
Long-Term Investments	-	-	-	1,876	1,847	-
Goodwill	-	106.74	106.74	106.74	39.23	72.19
Other Intangible Assets	156.95	55.01	64.33	73.44	39.71	141.33
Long-Term Deferred Tax Assets	32.95	32.95	-	-	-	4.12
Other Long-Term Assets	7.19	10.37	26.46	5.59	4.58	10.93
Total Assets	1,417	1,878	2,747	4,040	4,364	3,314
Accounts Payable	13.81	12	5.36	3.94	0.05	28.26
Accrued Expenses	-	113.03	98.01	73.09	68.33	73.19
Current Portion of Leases	45.45	54.56	47.15	36.69	14.53	23.53
Current Income Taxes Payable	-	-	37.97	56.78	66.74	41.75
Current Unearned Revenue	10.13	4.51	3.11	0.86	0.65	11.13
Other Current Liabilities	112.96	31.54	30.16	27.17	10	19.73
Total Current Liabilities	182.34	215.64	221.76	198.51	160.3	197.59
Long-Term Debt	-	-	-	-	-	12.94
Long-Term Leases	90.8	113.84	139.59	162.22	15.71	456.3
Long-Term Deferred Tax Liabilities	11.39	12.36	14.31	15.74	-	-
Total Liabilities	284.53	341.84	375.65	376.48	176	666.83
Common Stock	922.45	922.45	922.45	878.4	732.34	665.03
Additional Paid-In Capital	1,342	1,339	1,341	1,344	1,349	1,933
Retained Earnings	-1,184	-792.94	31.25	1,355	2,072	-525.91
Treasury Stock	-	-5.25	-10.6	-10.6	-10.6	-20.48
Comprehensive Income & Other	23.69	56.73	36.18	30.94	-12.49	-6.68
Total Common Equity	1,104	1,520	2,320	3,597	4,130	2,045
Minority Interest	28.74	15.71	51.51	66.1	58.15	602.47
Shareholders' Equity	1,133	1,536	2,371	3,664	4,188	2,648
Total Liabilities & Equity	1,417	1,878	2,747	4,040	4,364	3,314
Total Debt	136.25	168.4	186.74	198.91	30.24	492.76
Net Cash (Debt)	661.81	1,039	1,955	1,348	2,320	1,693
Net Cash Growth	-54.29%	-46.87%	45.01%	-41.87%	36.98%	0.68%
Net Cash Per Share	7.17	11.27	21.24	14.65	25.19	18.48
Filing Date Shares Outstanding	92.31	92.14	92.04	92.02	92.02	91.63
Total Common Shares Outstanding	92.31	92.14	92.04	92.02	92.02	91.63
Working Capital	735.5	1,102	2,006	1,439	2,230	2,222
Book Value Per Share	11.96	16.50	25.21	39.10	44.89	22.32
Tangible Book Value	946.9	1,358	2,149	3,417	4,051	1,832
Tangible Book Value Per Share	10.26	14.74	23.35	37.14	44.03	19.99
Machinery	-	229.55	178.49	168.97	46.34	239.52
Leasehold Improvements	-	84.96	46.22	45.6	6.43	74.41

Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.